|Bid||7.950 x 800|
|Ask||7.960 x 1100|
|Day's Range||7.563 - 7.976|
|52 Week Range||5.010 - 9.420|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Under its immunology program, Nektar Therapeutics (NKTR) is developing NKTR-358 in collaboration with Eli Lilly and Company (LLY).
Nektar Therapeutics (NKTR), a research-focused biopharmaceutical company, is developing a strong pipeline of product candidates that make use of its polymer conjugate technology platforms. This pipeline includes investigational drugs for the treatment of cancer, autoimmune disease, and chronic pain.
In August, Opko Health completed the enrollment of its worldwide Phase 3 trial of somatrogon in children with GHD (growth hormone deficiency). In July, Health Canada approved Rayaldee, a product of Opko Health and its partner Vifor Fresenius Medical Care Renal Pharma (VFMCRP), for commercialization in the Canadian market for the treatment of individuals with secondary hyperthyroidism who are at stage 3 or stage 4 of chronic kidney disease and have vitamin D insufficiency. In July, Opko Health announced the completion of its enrollment of 110 candidates for the initiation of its Phase 2b dose escalation clinical study of OPK88003, an injectable oxyntomodulin drug with GLP-1 and glucagon dual agonist activity for the treatment of individuals with Type 2 diabetes and obesity.
In the second quarter, Opko Health reported a net loss of $6.2 million compared to a net loss of $16.9 million in Q2 2017. In the first half of 2018, it reported a net loss of $49.3 million compared to a net loss of $51.4 million in the first half of 2017. In the second quarter, it reported a diluted loss per share of $0.01 compared to a loss of $0.04 in Q2 2017. In the first half of 2018, it reported a diluted net loss per share of $0.09 compared to a diluted net loss per share of $0.11 in the first half of 2017.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 31) Allakos Inc (NASDAQ: ALLK ) (listed July 19 following its IPO) ...
On a per-share basis, the New York-based company said it had a loss of 20 cents. The biopharmaceutical company posted revenue of $3.9 million in the period. Progenics shares have risen 34 percent since ...
The FDA's approval of Azedra followed clinical trails of the rare cancer therapy conducted at the University of Pennsylvania's Abramson Cancer Center in Philadelphia.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Apple Inc. (NASDAQ: AAPL ) is scheduled to release ...
Stalwarts like Twitter (NYSE:TWTR) and Facebook (NASDAQ:FB), both of which set the pace for the rest of the market, continued last week’s tumbles. Progenics Pharmaceuticals (NASDAQ:PGNX) hammered out an 8% gain following news that one of its drugs won an approval from the FDA, and Advanced Micro Devices (NASDAQ:AMD) advanced more than 2% on Monday, still fueled by last week’s impressive earnings beat. With that as the backdrop, the stock charts of Netflix (NASDAQ:NFLX), Unum Group (NYSE:UNM) and Dentsply Sirona (NASDAQ:XRAY) say they’re the best-grounded trading setups … at least as it stands right now.
The U.S. Food and Drug Administration (FDA) on Monday approved Progenics Pharmaceuticals Inc's treatment for two types of rare adrenal gland tumors, making it the first drug approved in the United States for this use. The drug, Azedra, was approved to treat patients above the age of 12 who have either of the two tumors - pheochromocytoma or paraganglioma - and require anti-cancer therapy, the FDA said https://bit.ly/2Ovz75p. The two tumor types affect the adrenal gland that releases the adrenaline hormone, which triggers the body's defense mechanism.
The U.S. Food and Drug Administration on Monday approved Progenics Pharmaceuticals Inc's treatment for two types of tumors. The drug, Azedra, was approved to treat some patients above the age of 12 who ...
Below is a list of notable corporate events for the week beginning July 30. Note, this list is not comprehensive and all dates are subject to change. All times are ET. View more earnings on AMZN Monday ...
It’s time to analyze how the first half turned out to be for pharma and biotech stocks in terms of FDA decisions. Key FDA approvals in the first half included Amgen (NASDAQ:AMGN)/Novartis’s first CGRP antibody Aimovig/erenumab for prevention of migraine, Johnson & Johnson’s (NYSE:JNJ) next-generation oral androgen receptor (“AR”) inhibitor Erleada (apalutamide) for pre-metastatic prostate cancer (CRPC), Vertex Pharmaceuticals’ (NASDAQ:VRTX) third medicine to treat the underlying cause of CF, Symdeko, which is a combination of tezacaftor and ivacaftor and BioMarin Pharmaceuticals’ Palynziq to treat phenylketonuria (PKU). FDA Decision on Indivior’s Schizophrenia Injection RBP-7000: On Jul 28, the FDA is expected to give its decision on Indivior‘s (OTCMKTS:INVVY) RBP-7000, which has been developed for the treatment of schizophrenia.
In this article I am going to calculate the intrinsic value of Progenics Pharmaceuticals Inc (NASDAQ:PGNX) using the discounted cash flows (DCF) model. If you want to learn more aboutRead More...
Zacks.com featured highlights include: VASCO Data, Progenics, Denny's, Columbus McKinnon and Equity Commonwealth
The New York-based company said it had a loss of 19 cents per share. The biopharmaceutical company posted revenue of $3.2 million in the period. Progenics shares have climbed 16 percent since the beginning ...
Zacks.com featured highlights include: Camtek, Progenics Pharmaceuticals, Denny's and Dropbox
Progenics Pharmaceuticals Inc’s (NASDAQ:PGNX): Progenics Pharmaceuticals, Inc. develops medicines and other technologies to target and treat cancer in the United States and internationally. On 31 December 2017, the US$607.45M market-capRead More...